Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
Status:
Terminated
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetics, safety and tolerability of brexpiprazole administered
subcutaneously or intramuscularly in adults with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.